HBOT adjunct therapy in hospitalized UC patients, San Diego
84 samples from hospitalized ulcerative colitis patients (adults and elderly) in San Diego, CA, USA, studying hyperbaric oxygen therapy as an adjunct intervention to standard treatment. machine-written summary
84 samples · 84 runs · US · Adult · 2022 · 52.7 Mbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 1,013 sample values (age, collection date, country, health condition, health condition detail, intervention, intervention detail, latitude) |
| ✓ Abstract / description | 44 sample values (health condition, health condition detail) |
| ○ Full text | read; no usable statement or table · PMC9117812 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Other administered intervention (see intervention_detail) design single_arm_before_after · population ulcerative_colitis · Hyperbaric oxygen therapy as adjunct to steroids for UC flares
“hyperbaric oxygen therapy (HBOT) as an adjunct” — bioproject.description (study level; per-sample arms are in the intervention column below)
longitudinal
22 of 49 people sampled more than once (57 samples; median 2, up to 4 per person) · follow-up median 9 d (max 12 mo) · median interval between samples 5 d (time from timepoint numbers, unit from the stated sampling schedule). Schedule stated by the source: “Stool collected at baseline (day0/day1) and follow-up days 3, 5, and 10 during hospitalization for UC flare.”; stated follow-up 10 d.
Each row is one person (22 shown); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 4 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 84 | 100% | ||||
| country | 84 | 100% | 84 | |||
| health_condition | 84 | 100% | 62 | 22 | ||
| subject_id | 84 | 100% | 84 | |||
| detailed_location | 84 | 100% | ||||
| health_condition_detail | 84 | 100% | 62 | 22 | ||
| latitude | 84 | 100% | 84 | |||
| location_locality | 84 | 100% | 84 | |||
| location_region | 84 | 100% | 84 | |||
| longitude | 84 | 100% | 84 | |||
| collection_date | 83 | 99% | 83 | |||
| age_at_collection_days | 62 | 74% | 62 | |||
| intervention | 62 | 74% | 62 | |||
| intervention_detail | 62 | 74% | 62 | |||
| sex | 58 | 69% | 58 | |||
| timepoint_label | 58 | 69% | 58 |
- The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients. 2022 PMID 35378331 PMC9117812 own_data
- Ulcerative Colitis Host-Microbiome Response to Hyperbaric Oxygen Therapy 2022 own_data
Archive description
Hyperbaric oxygen therapy (HBOT) markedly increases tissue oxygen delivery. Case series suggest it may have a potential therapeutic benefit in ulcerative colitis (UC). We investigated the therapeutic potential of HBOT as an adjunct to steroids for UC flares requiring hospitalization. Ulcerative colitis (UC) is a chronic inflammatory bowel disease which significantly affects the lives of nearly 1 million Americans. It is estimated that 25% of patients will need hospitalization for acute moderate to severe flares. Although colectomy is curative, it can be associated with significant morbidity, mortality and a reduction in quality of life. The mainstay of medical therapy for these patients is high dose intravenous steroids but approximately one-third of patients will be refractory and require second line rescue therapy with either cyclosporine or Infliximab, both of which are associated with a lack of significant efficacy in maintaining remission over the long term. Furthermore, corticosteroids have considerable long-term consequences and these immune suppressive drugs are associated with life-threatening infections and lymphomas. In an attempt to address this gap, we investigated the potential application of hyperbaric oxygen therapy (HBOT) as an adjunct to standard medical treatment. In a small phase 2A pilot study of 18 hospitalized UC patients, we were able to demonstrate a statistically significant increase in response, remission, and trend towards significance for avoidance of colectomy. We are now preparing for a phase 2B study in anticipation of a phase 3 registration trial and a multi-PI R01
How this project entered the registry
Classified as human gut / stool / blood / tissue / internal fluids shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site external_curation.infant_catalog · “body_site_call gut”
- body site study.description · “(HBOT) markedly increases tissue oxygen delivery. Case”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMEA12363447 | age_at_collection_days | 10957.5 | R1 | 0.90 | sample.attr.host_age | 30 |
| SAMEA12363447 | collection_date | 2017 | R1 | 0.85 | biosample.attribute:collection_timestamp | 2017 |
| SAMEA12363447 | country | US | R1 | 0.90 | sample.attr.geo_loc_name | USA:CA:San Diego |
| SAMEA12363447 | health_condition | ulcerative_colitis | R1 | 0.90 | biosample_attr | ulcerative colitis |
| SAMEA12363551 | health_condition | ulcerative_colitis | R4 | 0.50 | paper.abstract | HBOT reduces host neutrophil STAT3 and azurophilic granule activity in UC patients |
| SAMEA12363447 | health_condition_detail | ulcerative colitis | R1 | 0.90 | sample.attr.disease | ulcerative colitis |
| SAMEA12363551 | health_condition_detail | UC patients | R4 | 0.50 | paper.abstract | HBOT reduces host neutrophil STAT3 and azurophilic granule activity in UC patients |
| SAMEA12363447 | intervention | placebo | R1 | 0.90 | biosample.attribute:treatment_group | treatment_group: sham |
| SAMEA12363447 | intervention_detail | sham HBOT placebo arm | R1 | 0.90 | biosample.attribute:treatment_group | treatment_group: sham |
| SAMEA12363447 | latitude | 32.8420 | R1 | 0.90 | biosample.attribute:latitude+longitude | 32.842 -117.258 |
| SAMEA12363447 | location_locality | San Diego | R1 | 0.85 | biosample.attribute:geo_loc_name | USA:CA:San Diego |
| SAMEA12363447 | location_region | California | R1 | 0.75 | biosample.attribute:geo_loc_name | USA:CA:San Diego |
| SAMEA12363447 | longitude | -117.2580 | R1 | 0.90 | biosample.attribute:latitude+longitude | 32.842 -117.258 |
| SAMEA12363447 | sex | male | R1 | 0.90 | sample.attr.sex | male |
| SAMEA12363447 | subject_id | UPMC2 | R1 | 0.85 | sample.attr.host_subject_id | UPMC2 |
| SAMEA12363447 | timepoint_label | 1 | R1 | 0.85 | sample.attr.day | 1 |
Sequencing
84 runs over 84 samples · mean 0.54 Gbp per run (median 52.7 Mbp, total 45.63 Gbp; 84 runs with a base count) · layout PAIRED 84 · platform ILLUMINA 84 · models Illumina NovaSeq 6000 (84) · 5% of runs with a Sandpiper profile · first public 2022-01-19
Authors (0)
No author record.
Downloads
PRJEB50260.csv.gz (3.7 KB) · parquet (75.9 KB) — all 84 samples, every field with route and confidence · PRJEB50260_determinations.csv.gz (8.1 KB) — 1,057 evidence rows